Category: Clinical Trial Update Region: Asia · Korea, Republic of Company: Lemonex Inc

Lemonex, mRNA-DegradaBALL vaccine LEM-mR203 clinical phase 1 trial IND submission

Lemonex, mRNA-DegradaBALL vaccine LEM-mR203 clinical phase 1 trial IND submission
Lemonex Inc., a biotechnology company pioneering messenger RNA (mRNA) and siRNA therapeutics based on a novel nanoparticle drug delivery system announced on the 14h of February that an Investigational New Drug (IND) application has been submitted to the Ministry of Food and Drug Safety (MFDS) for mRNA vaccine LEM-mR203 with its nano-drug delivery platform, DegradaBALL

Found this useful? Share it with your team.

Welcome Back Sign in to Continue

Don't Have an Account? Sign Up!
Forgot Password?

Create your Account!

Don't Have an Account? Sign Up!